Lineage Cell Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount
Lineage Cell Therapeutics, Inc. (LCTX) reported Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount of $365.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherReconcilingItems · last filed 2026-03-05
- Lineage Cell Therapeutics, Inc. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2025 was $365.00K.
| Period end | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month |
|---|---|
| 2025-12-31 | $365.00K 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |